Presentation of Research Achievements of CSPC at the Annual Meeting of AACR

The 2023 Annual Meeting of the American Association for Cancer Research (AACR) was held, covering the latest global studies on many cutting-edge advances, new target exploration, clinical drug breakthroughs, new technologies and new ideas, and it has also become a stage for many companies to seek opportunities and show their strength. As the most popular track for innovative drugs, multinational pharmaceutical companies are making breakthroughs, and Chinese companies are making steady progress, jointly showing multiple important progress in the field of ADC drugs at AACR. 

The preclinical study data of SYSA1801 (EO-3021) project of CSPC were presented at a major medical conference for the first time. 

SYSA1801, a Claudin 18.2 product developed by CSPC, is composed of a monoclonal antibody (mAb) targeting Claudin 18.2 and a monomethyl auristatin E (MMAE) combined via a cleavable junction (DAR=2). Claudin 18.2 (CLDN 18.2) is a tight junction protein commonly expressed only on the gastric mucosa and overexpressed in the stomach, pancreas, esophagus, ovary, lung, and other solid tumors. 

In July 2022, CSPC announced to grant Elevation Oncology a worldwide interest in the development and commercialization of SYSA1801 (EO-3021) outside of Greater China with a down payment of $27 million, potential development and regulatory milestone payments of up to $148 million, and possible sales milestone payments of up to $1.02 billion.